Home » Beiträge » 10078

View Beitrag #10078

ID	10078
Ident	[ImpfNL-10/2023] Kundenbeitrag: Sanofi Efluelda (MB)
Titel	Efluelda® - Effektiver Impfschutz mit Hochdosis-Influenza-Impfstoff
Balkentitel	SANOFI INFORMIERT
Created	2023-10-17 11:00:25
Veraltet	0
typ_id	Universal 2023
sub_typ_id	Kundenbeitrag
html	<table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="right" style="padding:0;Margin:0;padding-bottom:5px;padding-top:5px;padding-right:0;padding-left:20px;background-color: #e0e0e0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#777777;font-size:12px !important;"><span style="background:transparent">Anzeige</span></p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Efluelda<sup style="line-height:0;">®</sup> – effektiver Impfschutz mit Hochdosis-Influenza-Impfstoff</h2> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;background-color:#ffffff;padding-top:20px"> <!--[if mso]> <table style="width:660px" cellpadding="0" cellspacing="0"> <tr> <td style="width:340px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:340px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:0px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Mit zunehmendem Alter wird das Immunsystem schwächer. Die Folge: Die Abwehr von Infektionen und das Ansprechen auf Impfungen sind beeinträchtigt.<sup style="line-height:0;">1</sup> Als Systemerkrankung kann die Influenza vor allem bei Menschen ab 60 das <a href="https://www.meindap.de/impf-nl-efluelda-2023-10-18" target="_blank" title="Zur Website www.campus.sanofi" style="mso-line-height-rule:exactly;text-decoration:none;color:#005CA9">Risiko für Komplikationen</a> stark erhöhen.<sup style="line-height:0;">2</sup> Eine Influenza-Impfung kann helfen, das Risiko von Influenza und influenzabedingten kardiovaskulären Komplikationen zu reduzieren.<sup style="line-height:0;">4</sup></p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> <td style="width:20px"></td> <td style="width:320px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:320px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;padding-right:20px;font-size:0" class="pt-20 pr-0"><img alt="" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none" src="https://www.deutschesapothekenportal.de/newsletter/2023q4/newsletter_2023-10-18_g1.png"></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> </tr> </table> <![endif]--> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;background-color:#ffffff;padding-top:20px"> <!--[if mso]> <table style="width:660px" cellpadding="0" cellspacing="0"> <tr> <td style="width:340px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:340px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:0px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Die STIKO empfiehlt allen ab 60 die Impfung mit einem tetravalenten Hochdosis-Influenza-Impfstoff.<sup style="line-height:0;">5</sup></p> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px"><a href="https://mein.sanofi.de/produkte/efluelda/downloads?id=/resources/SPC/ChronID-002096/data&pdfName=ChronID-002096" target="_blank" title="Zur Website mein.sanofi.de" style="mso-line-height-rule:exactly;text-decoration:none;color:#005CA9">Efluelda<sup style="line-height:0;">®</sup></a> ist der einzige tetravalente Hochdosis-Influenza-Impfstoff<sup style="line-height:0;">3</sup>, der für einen verbesserten Influenza-Impfschutz gegenüber konventionellen, standarddosierten Influenza-Impfstoffen von Menschen ab 60 Jahren entwickelt wurde.</p> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Was Efluelda<sup style="line-height:0;">®</sup> leisten kann, lesen Sie hier:</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> <td style="width:20px"></td> <td style="width:320px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:320px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;padding-right:20px;font-size:0" class="pt-20 pr-0"><a href="https://www.deutschesapothekenportal.de/newsletter/2023q4/DAP-Impf-News-Oktober-2023-Sanofi-Efluelda.png" target="_blank"><img alt="" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none" src="https://www.deutschesapothekenportal.de/newsletter/2023q4/newsletter_2023-10-18_g2.png"></a></td> </tr> <tr> <td align="right" class="es-text-3633" style="padding:0;Margin:0;padding-right:20px;font-size:12px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#555;font-size:12px">© Sanofi-Aventis Deutschland GmbH</p> <br> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> </tr> </table> <![endif]--> </td> </tr> <tr> <td align="center" style="Margin:0; padding: 20px 20px 20px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a href="https://www.campus.sanofi/de/produkte/impfstoffe/efluelda?restrictedaccess=98d4d37fe91b4ce593d28ebe5e7431c6&utm_source=GER-847-ADV-D3-001-MAT-DE-2302997&utm_medium=Advertorial&utm_campaign=GER-VAC-EFL-HCP-SAN-Efluelda-Influenza-Saison-2023-2024-und-Vorverkauf-2024-2025-20230601&utm_content=GER-847-ADV-D3-001-MAT-DE-2302997-VWE-deutschesapothekerportaluelda?utm_source=GER-847-ADV-D3-001-MAT-DE-2302997&utm_medium=Advertorial&utm_campaign=GER-VAC-EFL-HCP-SAN-Efluelda-Influenza-Saison-2023-2024-und-Vorverkauf-2024-2025-20230601&utm_content=GER-847-ADV-D3-001-MAT-DE-2302997-VWE-deutschesapothekerportal" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Jetzt informieren</a> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:20px;padding-left:20px;padding-top:10px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#555555;font-size:12px"> 1 Aw D Silva, AB. Palmer DB. Immunology 2007; 120(4):435-46. <a href="https://doi.org/10.1111/j.1365-2567.2007.02555.x" target="_blank" title="Zur Website doi.org" style="mso-line-height-rule:exactly;text-decoration:none;color:#005CA9">https://doi.org/10.1111/j.1365-2567.2007.02555.x</a><br> 2 <a href="https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/01_21.pdf?__blob=publicationFile" target="_blank" title="Zur Website www.rki.de" style="mso-line-height-rule:exactly;text-decoration:none;color:#005CA9">RKI. Epid Bull 2021; 1: 3-25</a><br> 3 <a href="https://www.pei.de/DE/arzneimittel/impfstoffe/influenza-grippe/influenza-node.html" target="_blank" title="Zur Website www.pei.de" style="mso-line-height-rule:exactly;text-decoration:none;color:#005CA9">PEI. Arzneimittel. Impfstoffe. Saisonale Influenzaimpfstoffe 2023/2024</a> (letzter Zugriff: 25.7.2023)<br> 4 Udell JA. et al. JAMA. 2013;310(16):1711-20. <a href="https://doi.org/10.1001/jama.2013.279206" target="_blank" title="Zur Website doi.org" style="mso-line-height-rule:exactly;text-decoration:none;color:#005CA9">https://doi.org/10.1001/jama.2013.279206</a><br> 5 RKI. Epid Bull 2023;4:1-68</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>
Typo3Html	<table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="right" style="padding:0;Margin:0;padding-bottom:5px;padding-top:5px;padding-right:0;padding-left:20px;background-color: #e0e0e0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#777777;font-size:12px !important;"><span style="background:transparent">Anzeige</span></p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Efluelda<sup style="line-height:0;">®</sup> – effektiver Impfschutz mit Hochdosis-Influenza-Impfstoff</h2> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;background-color:#ffffff;padding-top:20px"> <!--[if mso]> <table style="width:660px" cellpadding="0" cellspacing="0"> <tr> <td style="width:340px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:340px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:0px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Mit zunehmendem Alter wird das Immunsystem schwächer. Die Folge: Die Abwehr von Infektionen und das Ansprechen auf Impfungen sind beeinträchtigt.<sup style="line-height:0;">1</sup> Als Systemerkrankung kann die Influenza vor allem bei Menschen ab 60 das <a href="https://www.meindap.de/impf-nl-efluelda-2023-10-18" target="_blank" title="Zur Website www.campus.sanofi" style="mso-line-height-rule:exactly;text-decoration:none;color:#005CA9">Risiko für Komplikationen</a> stark erhöhen.<sup style="line-height:0;">2</sup> Eine Influenza-Impfung kann helfen, das Risiko von Influenza und influenzabedingten kardiovaskulären Komplikationen zu reduzieren.<sup style="line-height:0;">4</sup></p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> <td style="width:20px"></td> <td style="width:320px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:320px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;padding-right:20px;font-size:0" class="pt-20 pr-0"><img alt="" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none" src="https://www.deutschesapothekenportal.de/newsletter/2023q4/newsletter_2023-10-18_g1.png"></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> </tr> </table> <![endif]--> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;background-color:#ffffff;padding-top:20px"> <!--[if mso]> <table style="width:660px" cellpadding="0" cellspacing="0"> <tr> <td style="width:340px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:340px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:0px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Die STIKO empfiehlt allen ab 60 die Impfung mit einem tetravalenten Hochdosis-Influenza-Impfstoff.<sup style="line-height:0;">5</sup></p> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px"><a href="https://mein.sanofi.de/produkte/efluelda/downloads?id=/resources/SPC/ChronID-002096/data&pdfName=ChronID-002096" target="_blank" title="Zur Website mein.sanofi.de" style="mso-line-height-rule:exactly;text-decoration:none;color:#005CA9">Efluelda<sup style="line-height:0;">®</sup></a> ist der einzige tetravalente Hochdosis-Influenza-Impfstoff<sup style="line-height:0;">3</sup>, der für einen verbesserten Influenza-Impfschutz gegenüber konventionellen, standarddosierten Influenza-Impfstoffen von Menschen ab 60 Jahren entwickelt wurde.</p> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:10px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Was Efluelda<sup style="line-height:0;">®</sup> leisten kann, lesen Sie hier:</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> <td style="width:20px"></td> <td style="width:320px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:320px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;padding-right:20px;font-size:0" class="pt-20 pr-0"><a href="https://www.deutschesapothekenportal.de/newsletter/2023q4/DAP-Impf-News-Oktober-2023-Sanofi-Efluelda.png" target="_blank"><img alt="" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none" src="https://www.deutschesapothekenportal.de/newsletter/2023q4/newsletter_2023-10-18_g2.png"></a></td> </tr> <tr> <td align="right" class="es-text-3633" style="padding:0;Margin:0;padding-right:20px;font-size:12px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#555;font-size:12px">© Sanofi-Aventis Deutschland GmbH</p> <br> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> </tr> </table> <![endif]--> </td> </tr> <tr> <td align="center" style="Margin:0; padding: 20px 20px 20px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a href="https://www.campus.sanofi/de/produkte/impfstoffe/efluelda?restrictedaccess=98d4d37fe91b4ce593d28ebe5e7431c6&utm_source=GER-847-ADV-D3-001-MAT-DE-2302997&utm_medium=Advertorial&utm_campaign=GER-VAC-EFL-HCP-SAN-Efluelda-Influenza-Saison-2023-2024-und-Vorverkauf-2024-2025-20230601&utm_content=GER-847-ADV-D3-001-MAT-DE-2302997-VWE-deutschesapothekerportaluelda?utm_source=GER-847-ADV-D3-001-MAT-DE-2302997&utm_medium=Advertorial&utm_campaign=GER-VAC-EFL-HCP-SAN-Efluelda-Influenza-Saison-2023-2024-und-Vorverkauf-2024-2025-20230601&utm_content=GER-847-ADV-D3-001-MAT-DE-2302997-VWE-deutschesapothekerportal" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Jetzt informieren</a> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-bottom:20px;padding-left:20px;padding-top:10px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#555555;font-size:12px"> 1 Aw D Silva, AB. Palmer DB. Immunology 2007; 120(4):435-46. <a href="https://doi.org/10.1111/j.1365-2567.2007.02555.x" target="_blank" title="Zur Website doi.org" style="mso-line-height-rule:exactly;text-decoration:none;color:#005CA9">https://doi.org/10.1111/j.1365-2567.2007.02555.x</a><br> 2 <a href="https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/01_21.pdf?__blob=publicationFile" target="_blank" title="Zur Website www.rki.de" style="mso-line-height-rule:exactly;text-decoration:none;color:#005CA9">RKI. Epid Bull 2021; 1: 3-25</a><br> 3 <a href="https://www.pei.de/DE/arzneimittel/impfstoffe/influenza-grippe/influenza-node.html" target="_blank" title="Zur Website www.pei.de" style="mso-line-height-rule:exactly;text-decoration:none;color:#005CA9">PEI. Arzneimittel. Impfstoffe. Saisonale Influenzaimpfstoffe 2023/2024</a> (letzter Zugriff: 25.7.2023)<br> 4 Udell JA. et al. JAMA. 2013;310(16):1711-20. <a href="https://doi.org/10.1001/jama.2013.279206" target="_blank" title="Zur Website doi.org" style="mso-line-height-rule:exactly;text-decoration:none;color:#005CA9">https://doi.org/10.1001/jama.2013.279206</a><br> 5 RKI. Epid Bull 2023;4:1-68</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>

Newsletter 2023

2023-10-18

Beitrag per e-mail verschicken

Auswertungsvorlage anzeigen

Statistik anzeigen